Canaccord analyst Dewey Steadman maintained a Buy rating on ANI Pharmaceuticals and raised his price target to $90 from $80 following the company's "solid" Q1 earnings report. In a research note to investors, Steadman says ANI is set for several value-creating launches this year including the remaining Concerta strengths, a generic Aggrenox, a vancomycin oral solution and an undisclosed approved generic priority review product. On the heels of this launch activity is the Cortrophin filing, which is still on track for 1Q20 with a potential launch in the second half of 2020. With a solid generics portfolio, a deep pipeline library with several meaningful opportunities and continued upside optionality associated with the Cortrophin asset, Steadman says he is still positive on ANI shares, even with the shares' recent outperformance